Bioeq
Bioeq AG is a Swiss biopharmaceutical joint venture (Polpharma Biologics and Formycon) that develops, manufactures, and out-licenses the Ranibizumab biosimilar of Lucentis globally, serving ophthalmology patients with retinal disorders via regional pharmaceutical commercialization partners.
- Company typePrivate
- Founded-
- HeadquartersZug, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bioeq does
Bioeq AG is a Swiss biopharmaceutical joint venture, equally owned by Polpharma Biologics Group and Formycon AG, headquartered in Zug, Switzerland. The company develops, manufactures, licenses, and commercializes biosimilars globally, with a focused portfolio centered on Ranibizumab (FYB201), a monoclonal antibody biosimilar to Roche/Genentech's Lucentis. Ranibizumab targets vascular endothelial growth factor (VEGF) and is indicated for retinal disorders including age-related macular degeneration (AMD), choroidal neovascularization (CNV), retinal vein occlusion, and diabetic retinopathy. The same molecule is marketed under multiple brand names across jurisdictions: Cimerli (US, 2022 FDA approval as the first interchangeable Lucentis biosimilar), Ranivisio (European Commission and Swissmedic, launched commercially in Europe starting November 2025 with Teva), Ongavia (UK MHRA, 2022), NUFYMCO (US, 2025 FDA approval commercialized with Zydus Lifesciences), and BioUcenta (Africa via Bio Usawa).
Bioeq operates an asset-light, B2B licensing and royalty business model. The company itself is small (1-10 employees) and handles development, manufacturing oversight, and registration through its JV parents' capabilities, while out-licensing commercialization rights to established regional pharmaceutical partners in each territory. Key partners include Teva (Europe, Israel), Zydus Lifesciences (US), MS Pharma (Middle East/Africa), Bio Usawa Biotechnology (Rwanda/Africa), Actor Pharma (Australia), Megalabs (Latin America), and Horus Pharma (selected European countries). Pricing is set independently by each partner in its market and is not publicly disclosed by Bioeq. Its customers are therefore pharmaceutical licensees rather than end prescribers or patients, with end-user demand driven by ophthalmologists, hospitals, clinics, and patients seeking affordable alternatives to the high-cost originator Lucentis.
Bioeq firmographics
Firmographics- Name
- Bioeq
- Legal name
- Bioeq AG
- Website
- https://bioeq.ch
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bioeq AG is a Swiss biopharmaceutical joint venture (Polpharma Biologics and Formycon) that develops, manufactures, and out-licenses the Ranibizumab biosimilar of Lucentis globally, serving ophthalmology patients with retinal disorders via regional pharmaceutical commercialization partners.
- Ownership category
- akta.pro rank
Bioeq industry classification
Industry- Product category
- Biosimilars
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Ophthalmology Pharmaceuticals (HLAIAAAL), Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance) (HLAAAHAJ), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)
Keywords
Where Bioeq is headquartered
LocationHeadquarters
- HQ city
- Zug
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Bioeq business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations
Revenue model
- Biosimilar Licensing and Commercialization: Bioeq develops biosimilars and out-licenses them to established pharmaceutical companies for commercialization in specific territories. Partners handle local registration, marketing, and distribution while Bioeq manages development, manufacturing, and supply.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
Bioeq product offering
Product offeringCore offering
Bioeq AG is a Swiss biopharmaceutical joint venture that develops, manufactures, and out-licenses biosimilars of biopharmaceutical products globally. Its core offering is a Ranibizumab biosimilar (FYB201) to Lucentis, approved by FDA, EMA, Swissmedic, UK MHRA, and Brazil's ANVISA for retinal disorders including age-related macular degeneration, choroidal neovascularization, retinal vein occlusion, and diabetic retinopathy. The company licenses commercialization rights to established pharmaceutical partners in each territory rather than selling directly, focusing on development, manufacturing, registration, and supply.
Product overview
Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG, focused on developing, producing, licensing, and commercializing biosimilars globally. The company's primary product is Ranibizumab, a biosimilar to Lucentis, which is marketed under multiple brand names across different markets: Cimerli (FDA-approved, US), Ranivisio (EC and Swissmedic-approved, Europe/Switzerland), and Ongavia (MHRA-approved, UK). In December 2025, Bioeq received FDA approval for NUFYMCO, an interchangeable biosimilar to Lucentis, which is commercialized in the US through a partnership with Zydus Lifesciences. The company operates through licensing agreements with established international pharmaceutical companies for global distribution.
Differentiator
Problem solved
Functional benefit
Products and services
- Ranivisio Biosimilar to Lucentis (ranibizumab) approved by the European Commission and Swissmedic for treating retinal disorders including age-related macular degeneration (AMD), choroidal neovascularization (CNV), retinal vein occlusion, and diabetic retinopathy. Marketed in Europe and Switzerland through partners including Teva.
- Cimerli Biosimilar to Lucentis (ranibizumab) approved by the US FDA as the first interchangeable biosimilar for treating retinal disorders including AMD and diabetic eye diseases. Previously commercialized in the US through partnership with Coherus BioSciences.
- Ongavia Biosimilar to Lucentis (ranibizumab) approved by the UK Medicines and Healthcare Regulatory Agency (MHRA) for the treatment of retinal disorders.
- NUFYMCO Interchangeable biosimilar to Lucentis (ranibizumab) approved by the US FDA in December 2025 for retinal disorders. Commercialized in the US through partnership with Zydus Lifesciences.
Quantifiable outcome
- First Lucentis biosimilar launched in Europe and first interchangeable biosimilar approved by FDA
Companies that use Bioeq
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Bioeq technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Bioeq partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered flagship, core and minor.
- Zydus LifesciencesflagshipZydus Lifesciences' subsidiary partnered with Bioeq to license and commercialize NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market following FDA approval on December 18, 2025. Bioeq manages development, manufacturing, and registration while Zydus handles commercialization in the US.
- Polpharma Biologics GroupcorePolpharma Biologics Group is one of the two parent companies forming the Bioeq joint venture. Together with Formycon AG, they established Bioeq AG to develop, produce, license and commercialize biosimilars globally.
- Formycon AGcoreFormycon AG is one of the two parent companies forming the Bioeq joint venture. Together with Polpharma Biologics Group, they established Bioeq AG to develop, produce, license and commercialize biosimilars globally.
- Bio Usawa Biotechnology Ltd.corePartnership for the commercialization of biosimilar products in Rwanda and Africa. Bio Usawa received approval for BioUcenta, the first biosimilar ranibizumab approved in Africa.
- Teva Pharmaceutical IndustriesflagshipTeva partnered with Bioeq and Formycon to launch Ranivisio, the first Lucentis biosimilar in Europe. Launch began in France with Germany and other countries to follow. Teva has agreements for major European markets and Israel.
- Actor PharmacoreLicensing agreement for commercialization of biosimilar products in Australia.
- MegalabscoreLicensing agreement for commercialization of biosimilar products in Latin America.
- Horus PharmacoreLicensing agreement for commercialization of biosimilar products in selected European countries.
- MS PharmacorePartnership for commercialization of Ranibizumab biosimilar in Middle East and Africa regions.
- Coherus BioSciencesminorPrevious partnership for US commercialization of biosimilar products (November 2019). Status appears historical as current US partnership is with Zydus.
Scale indicators2 records
Recent moves7 records
Expansion highlights6 records
Bioeq competitors and assessment
Company assessmentDirect peers
- Formycon AG: Co-developer and 50% parent of Bioeq AG. Formycon develops and out-licenses biosimilars including ranibizumab biosimilars (FYB201) and other ophthalmology and immunology assets, making it the closest structural and product comparable to Bioeq.
- Alvotech: Alvotech is a pure-play biosimilar developer and manufacturer with multiple approved biosimilars and a pipeline spanning ophthalmology, immunology, and oncology. Comparable to Bioeq as a biosimilar-focused company pursuing global approvals and partner-based commercialization.
- Celltrion: Celltrion develops, manufactures, and commercializes biosimilars (Remsima, Truxima, etc.) globally, including a ranibizumab biosimilar program. Highly comparable to Bioeq as a biosimilar developer with integrated manufacturing and partner-led commercialization in selected markets.
- Coherus BioSciences: Former US commercialization partner for Bioeq's ranibizumab biosimilar (Cimerli). Coherus is a US-focused biosimilar and immuno-oncology company commercializing Lucentis and other biosimilars, providing a direct read on US biosimilar commercial dynamics relevant to Bioeq via Zydus.
- Samsung Bioepis: Samsung Bioepis developed Byooviz, the first FDA-approved Lucentis biosimilar in the US, and is a global biosimilar developer across ophthalmology, immunology, and oncology. Directly competes with Bioeq in the Lucentis biosimilar space and uses a similar licensing-out commercialization model.
- Polpharma Biologics Group: 50% parent of Bioeq AG and an integrated biosimilar development and manufacturing organization. Operates CDMO and proprietary biosimilar businesses, making it structurally and operationally highly comparable to Bioeq while supplying much of Bioeq's underlying development and manufacturing backbone.
- Biocon Biologics: Biocon Biologics is a major global biosimilar developer and manufacturer with assets across oncology, immunology, and ophthalmology. It pursues a similar out-licensing and partner commercialization strategy and competes in the same regulatory jurisdictions as Bioeq.
Broad incumbents
- Amgen (Biosimilars): Amgen operates one of the largest biosimilar franchises (Amgevita, Mvasi, Kanjinti, etc.) and is the originator of several biologic reference products. Comparable as a large established biosimilar player with global commercialization capability, although not specialized solely in ophthalmology.
- Pfizer (Biosimilars): Pfizer has a broad biosimilars portfolio (Zirabev, Ruxience, Nivestym, etc.) following its Hospira and Mylan integration and competes across ophthalmology and other therapy areas. Comparable as a diversified incumbent with global commercialization reach relevant to biosimilar pricing and access dynamics.
Regional players
- Teva Pharmaceutical Industries: Teva is Bioeq's flagship European commercialization partner for Ranivisio and is also a major global biosimilars player (e.g., Truxima partnership) with a leading generics and biosimilars footprint in Europe and Israel. Comparable as the commercial counterpart that drives Bioeq's European revenue.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Bioeq financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioeq leadership team
Management profileNumber of profiles
Profiles7 records
Bioeq funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioeq M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioeq
What does Bioeq do?
Bioeq AG is a Swiss biopharmaceutical joint venture that develops, manufactures, and out-licenses biosimilars of biopharmaceutical products globally. Its core offering is a Ranibizumab biosimilar (FYB201) to Lucentis, approved by FDA, EMA, Swissmedic, UK MHRA, and Brazil's ANVISA for retinal disorders including age-related macular degeneration, choroidal neovascularization, retinal vein occlusion, and diabetic retinopathy. The company licenses commercialization rights to established pharmaceutical partners in each territory rather than selling directly, focusing on development, manufacturing, registration, and supply.
Is Bioeq a public or private company?
Bioeq is a private company. It is classified as corporate owned and is currently operating.
When was Bioeq founded?
Bioeq was founded in -1. It employs 1 to 10 people.
Where is Bioeq based?
Bioeq is headquartered in Zug, Switzerland, in the Europe region.
How does Bioeq make money?
One revenue line is on record: biosimilar Licensing and Commercialization.
Who are Bioeq's main competitors?
Direct peers on record are Formycon AG, Alvotech, Celltrion, Coherus BioSciences, Samsung Bioepis, Polpharma Biologics Group and Biocon Biologics. Broad incumbents are Amgen (Biosimilars) and Pfizer (Biosimilars). Teva Pharmaceutical Industries is listed as a regional player.
Does Bioeq have an API?
No public API is recorded for Bioeq.
What industry is Bioeq in?
Bioeq's product category is Biosimilars. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.